Explore Survodutide dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Survodutide (BI 456906) is a GLP-1 and glucagon receptor dual agonist developed by Boehringer Ingelheim and Zealand Pharma, studied in obesity and in metabolic dysfunction-associated steatohepatitis (MASH), where the glucagon arm is thought to add direct effects on liver fat and energy expenditure beyond GLP-1-driven appetite suppression. This data shows the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting Survodutide.
Survodutide is an investigational GLP-1/glucagon dual receptor agonist studied for weight management and metabolic-liver (MASH) research. It ships as a lyophilized powder you reconstitute with bacteriostatic water, so vendor quality comes down to what the certificate of analysis (COA) shows.
Survodutide binds both the GLP-1 receptor and the glucagon receptor with comparable potency. The GLP-1 arm produces the standard incretin effects (insulin secretion, glucagon suppression, slowed gastric emptying, appetite reduction). The glucagon arm — absent from semaglutide and tirzepatide — increases resting energy expenditure and accelerates hepatic lipolysis, the leading hypothesis for the molecule's large hepatic-fat-reduction signal in MASH.
Le Roux et al. (Lancet Diabetes Endocrinol 2024) reported the Phase 2 obesity trial: mean body-weight reduction of 18.7% at 46 weeks on the 4.8mg arm versus 2.0% on placebo, with a separate weekly-cohort showing similar efficacy. A Phase 2 MASH trial (Sanyal et al., NEJM 2024) reported that 47–62% of participants on the 2.4–6.0mg arms achieved a ≥30% reduction in liver fat content versus 14% on placebo at 48 weeks, with histologic improvement supporting the Breakthrough designation. Phase 3 SYNCHRONIZE-1 and SYNCHRONIZE-2 are enrolling, with primary readouts expected 2025–2026.
Survodutide has a reported half-life of ~6–7 days, and the dose intervals researchers model most often fall around once weekly. A roughly week-long half-life supports once-weekly dosing and builds to steady state over about 5 weeks, with substantial carryover from each dose to the next. It is catalogued under Weight Loss on WPA.
14 Survodutide reconstitution calculations have been logged by the WPA community. The most common dose entered is 600mcg (4 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (12 sessions). The most common dosing frequency is once weekly (3 logged protocols).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.